The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1
Open accessAbstract
BACKGROUND: Interferon alpha (IFN-alpha) activated cellular signalling is negatively regulated by inhibitory factors, including the suppressor of cytokine signalling (SOCS) family. The effects of host factors such as obesity on hepatic expression of these inhibitory factors in subjects with chronic hepatitis C virus (HCV) are unknown. OBJECTIVES: To assess the independent effects of obesity, insulin resistance, and steatosis on response to IFN-alpha therapy and to determine hepatic expression of factors inhibiting IFN-alpha signalling in obese and non-obese subjects with chronic HCV. METHODS: A total of 145 subjects were analysed to determine host factors associated with non-response to antiviral therapy. Treatment comprised IFN-alpha or peginterferon alpha, either alone or in combination with ribavirin. In a separate cohort of 73 patients, real time-polymerase chain reaction was performed to analyse hepatic mRNA expression. Immunohistochemistry for SOCS-3 was performed on liver biopsy samples from 38 patients with viral genotype 1 who had received antiviral treatment. RESULTS: Non-response (NR) to treatment occurred in 55% of patients with HCV genotypes 1 or 4 and 22% with genotypes 2 or 3. Factors independently associated with NR were viral genotype 1/4 (p < 0.001), cirrhosis on pretreatment biopsy (p = 0.025), and body mass index > or = 30 kg/m2 (p = 0.010). Obese subjects with viral genotype 1 had increased hepatic mRNA expression of phosphoenolpyruvate carboxy kinase (p = 0.01) and SOCS-3 (p = 0.047), in comparison with lean subjects. Following multivariate analysis, SOCS-3 mRNA expression remained independently associated with obesity (p = 0.023). SOCS-3 immunoreactivity was significantly increased in obesity (p = 0.013) and in non-responders compared with responders (p = 0.014). CONCLUSIONS: In patients with chronic HCV viral genotype 1, increased expression of factors that inhibit interferon signalling may be one mechanism by which obesity reduces the biological response to IFN-alpha.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link
Hotamisligil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1271 · Cited by 1,281
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression
Hui, J. M., Sud, A., Farrell, G. C., Bandara, P., Byth, K., Kench, J. G., McCaughan, G. W., & George, J. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.032 · Cited by 718
Ueki, K., Kondo, T., & Kahn, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5434-5446.2004 · Cited by 686
Association of Diabetes Mellitus and Chronic Hepatitis C Virus Infection
Mason, A. L., Lau, J. Y., Hoang, N., Qian, K., Alexander, G. J., Xu, L., Guo, L., Jacob, S., Regenstein, F. G., Zimmerman, R., et al. (1999) · Hepatology · doi:10.1002/hep.510290235 · Cited by 659
Senn, J. J., Klover, P. J., Nowak, I. A., Zimmers, T. A., Koniaris, L. G., Furlanetto, R. W., & Mooney, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210689200 · Cited by 620
Poynard, T., Ratziu, V., McHutchison, J., Manns, M., Goodman, Z., Zeuzem, S., Younossi, Z., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50267 · Cited by 604
Novel concepts in insulin regulation of hepatic gluconeogenesis
Barthel, A., & Schmoll, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00253.2003 · Cited by 515
SOCS: physiological suppressors of cytokine signaling
Krebs, D. L., & Hilton, D. J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.16.2813 · Cited by 463
Emanuelli, B., Peraldi, P., Filloux, C., Chavey, C., Freidinger, K., Hilton, D. J., Hotamisligil, G. S., & Van Obberghen, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104602200 · Cited by 449
Song, M. M., & Shuai, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.35056 · Cited by 395
Ueki, K., Kondo, T., Tseng, Y.-H., & Kahn, C. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402511101 · Cited by 384
Bressler, B. L., Guindi, M., Tomlinson, G., & Heathcote, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50350 · Cited by 358
O'Brien, R. M., Lucas, P. C., Forest, C. D., Magnuson, M. A., & Granner, D. K. (1990) · Science · doi:10.1126/science.2166335 · Cited by 357
Tumor necrosis factor alpha: a key component of the obesity-diabetes link
Hotamisligil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diabetes.43.11.1271 · Cited by 349
Bode, J. G., Ludwig, S., Ehrhardt, C., Erhardt, A., Albrecht, U., Schaper, F., Heinrich, P. C., & Häussinger, D. (2003) · The FASEB Journal · doi:10.1096/fj.02-0664fje · Cited by 312
Optimal therapy of hepatitis C
Di Bisceglie, A. M., & Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360716 · Cited by 297
Increased Risk of Type 2 Diabetes in Noncirrhotic Patients With Chronic Hepatitis C Virus Infection
Knobler, H., Schihmanter, R., Zifroni, A., Fenakel, G., & Schattner, A. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.4.355 · Cited by 292
TNF-α and insulin resistance: Summary and future prospects
Peraldi, P., & Spiegelman, B. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006865715292 · Cited by 286
Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis
Larrea, E. (1996) · Hepatology · doi:10.1053/jhep.1996.v23.pm0008591843 · Cited by 229
Host factors and failure of interferon-α treatment in hepatitis C virus
Gao, B., Hong, F., & Radaeva, S. (2004) · Hepatology · doi:10.1002/hep.20139 · Cited by 159
Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury
Walsh, M. J., Vanags, D. M., Clouston, A. D., Richardson, M. M., Purdie, D. M., Jonsson, J. R., & Powell, E. E. (2004) · Hepatology · doi:10.1002/hep.20179 · Cited by 144
Self-citationInterferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes
Radaeva, S., Jaruga, B., Hong, F., Kim, W., Fan, S., Cai, H., Strom, S. C., Liu, Y., El-Assal, O. N., & Gao, B. (2002) · Gastroenterology · doi:10.1053/gast.2002.32388 · Cited by 135
SOCS-1 and SOCS-3 inhibit IFN-α-induced expression of the antiviral proteins 2,5-OAS and MxA
Vlotides, G., Sörensen, A. S., Kopp, F. B., Zitzmann, K., Cengic, N., Brand, S., Zachoval, R., & Auernhammer, C. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.051 · Cited by 132
IL‐10 attenuates IFN‐α‐activated STAT1 in the liver: involvement of SOCS2 and SOCS3
Shen, X., Hong, F., Nguyen, V.-A., & Gao, B. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01905-0 · Cited by 122
Ueki, K., Kondo, T., & Kahn, C. R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.19.8762.2005 · Cited by 85
Hong, F., Nguyen, V.-A., & Gao, B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0908fje · Cited by 79
Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
Kaserer, Fiedler, Steindl, Müller, E., Wrba, & Ferenci (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00413.x · Cited by 78
Paul, C., Seiliez, I., Thissen, J., & Cam, A. L. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01395.x · Cited by 69
Akuta, N., Suzuki, F., Tsubota, A., Suzuki, Y., Someya, T., Kobayashi, M., Saitoh, S., Arase, Y., Ikeda, K., & Kumada, H. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00301-x · Cited by 55
Effect of Obesity on Pharmacokinetics and Biologic Effect of Interferon-alpha in Hepatitis C
Lam, N. P., PITRAK, D. L., Pharmd, R. S., Lau, A. H., Wiley, T. E., & Layden, T. J. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018865928308 · Cited by 50
Obesity and Its Nurturing Effect on Hepatitis C
McCullough, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50413 · Cited by 41
Banner, B. F., Barton, A. L., Cable, E. E., Smith, L., & Bonkovsky, H. L. (1995) · PubMed · Cited by 37
What is disrupting IFN-α's antiviral activity?
Mbow, M. L., & Sarisky, R. T. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.06.002 · Cited by 33
Dumoulin, F. L., Wennrich, U., Nischalke, H. D., Leifeld, L., Hp, F., Sauerbruch, T., & Spengler, U. (2001) · PubMed · Cited by 33
Lam, N. P., DeGuzman, L. J., PITRAK, D. L., & Layden, T. J. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02087706 · Cited by 29
Cited by
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
Global challenges in liver disease
Williams, R. (2006) · Hepatology · doi:10.1002/hep.21347 · Cited by 788
Moucari, R., Asselah, T., Cazals–Hatem, D., Voitot, H., Boyer, N., Ripault, M., Sobesky, R., Martinot–Peignoux, M., Maylin, S., Nicolas–Chanoine, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.010 · Cited by 546
Influenza A Virus Inhibits Type I IFN Signaling via NF-κB-Dependent Induction of SOCS-3 Expression
Pauli, E.-K., Schmolke, M., Wolff, T., Viemann, D., Roth, J., Bode, J. G., & Ludwig, S. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000196 · Cited by 275
García-Ruiz, I., Solís-Muñoz, P., Gómez-Izquierdo, É., Muñoz-Yagüe, M. T., Valverde, Á. M., & Solís-Herruzo, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.342709 · Cited by 22
Metadata
- Authors
- Walsh, M. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-04-01
- Volume
- 55
- Issue
- 4
- Pages
- 529-535
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2124182278
- Cited by
- 269
- References
- 43
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.